PET Imaging Quantifying 68Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer

被引：18

作者：

Cuda, Tahleesa J. ^{[1
,2
]}

Riddell, Andrew D. ^{[1
,2
]}

Liu, Cheng ^{[1
,3
,4
]}

Whitehall, Vicki L. ^{[1
,4
]}

Borowsky, Jennifer ^{[1
,2
,4
]}

Wyld, David K. ^{[1
,2
]}

Burge, Matthew E. ^{[1
,2
]}

Ahern, Elizabeth ^{[1
,2
,4
]}

Griffin, Alison ^{[4
]}

Lyons, Nicholas J. R. ^{[1
,2
]}

Rose, Stephen E. ^{[5
]}

Clark, David A. ^{[1
,2
]}

Stevenson, Andrew R. L. ^{[1
,2
]}

Hooper, John D. ^{[1
]}

Puttick, Simon ^{[5
]}

Thomas, Paul A. ^{[1
,2
,6
]}

机构：

[1] Univ Queensland, Brisbane, Qld, Australia

[2] Metro North Hosp & Hlth Serv, Brisbane, Qld, Australia

[3] Envoi Specialist Pathologists, Herston, Qld, Australia

[4] QIMR Berghofer Med Res Inst, Herston, Qld, Australia

[5] CSIRO, Herston, Qld, Australia

[6] Herston Imaging Res Facil, Herston, Qld, Australia

来源：

JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷 / 11期

关键词：

metastatic colorectal cancer; peptide receptor radionuclide therapy; PET; theranostics;

D O I：

10.2967/jnumed.119.233312

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

At diagnosis, 22% of colorectal cancer (CRC) patients have metastases, and 50% later develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as Lu-177-PSMA-617, is used to treat metastatic prostate cancer. Lu-177-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surface protein enriched in prostate cancer and the neovasculature of other solid tumors, including CRC. We performed Ga-68-PSMA-11 PET/CT imaging of 10 patients with metastatic CRC to assess metastasis avidity. Eight patients had lesions lacking avidity, and 2 had solitary metastases exhibiting very low avidity. Despite expression of PSMA in CRC neovasculature, none of the patients exhibited tumor avidity sufficient to be considered for Lu-177-PSMA-617 PRRT.

引用

页码：1576 / 1579

页数：4

共 50 条

[31] Physiological 68Ga-PSMA-11 Uptake in Dural Venous Sinuses
Kulkarni, Mukta
Joshi, Prathamesh Vijay
Kumar, Kritik
CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : e58 - e60
[32] Postdiurectic 68Ga-PSMA-11 PET/CT in Indeterminate Lesions
不详
JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (03) : 21N - 21N
[33] Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
Jannusch, Kai
Bruckmann, Nils Martin
Morawitz, Janna
Boschheidgen, Matthias
Quick, Harald H.
Herrmann, Ken
Fendler, Wolfgang P.
Umutlu, Lale
Stuschke, Martin
Hadaschik, Boris
Antoch, Gerald
Schimmoeller, Lars
Kirchner, Julian
EUROPEAN RADIOLOGY, 2024, 34 (07) : 4789 - 4800
[34] 68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer
Fassbind, Saskia
Ferraro, Daniela A.
Stelmes, Jean-Jacques
Fankhauser, Christian D.
Guckenberger, Matthias
Kaufmann, Philipp A.
Eberli, Daniel
Burger, Irene A.
Kranzbuhler, Benedikt
ANNALS OF NUCLEAR MEDICINE, 2021, 35 (10) : 1109 - 1116
[35] Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
Demirci, Emre
Sahin, Onur Erdem
Ocak, Meltem
Akovali, Burak
Nematyazar, Jamal
Kabasakal, Levent
NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (11) : 1169 - 1179
[36] Recurrent Brain Metastasis of Triple Negative Breast Cancer With High Uptake in 68Ga-PSMA-11 PET/CT
Arslan, Esra
Ergul, Nurhan
Karagoz, Yesim
Gedik, Arzu Algun
Cermik, Tevfik Fikret
CLINICAL NUCLEAR MEDICINE, 2021, 46 (02) : E106 - E108
[37] Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer
Chiu, Le Wen
Lawhn-Heath, Courtney
Behr, Spencer C.
Juarez, Roxanna
Perez, Paola M.
Lobach, Iryna
Bucknor, Matthew D.
Hope, Thomas A.
Flavell, Robert R.
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (12) : 1779 - 1785
[38] 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept
Ahmadzadehfar, Hojjat
Azgomi, Kambiz
Hauser, Stefan
Wei, Xiao
Yordanova, Anna
Gaertner, Florian C.
Kuerpig, Stefan
Strunk, Holger
Essler, Markus
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (03) : 438 - 444
[39] Imaging Characteristics of Coexisting Metastatic Papillary Thyroid Cancer and Prostate Cancer on 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT
Lu, Yang
CLINICAL NUCLEAR MEDICINE, 2022, 47 (09) : 820 - 821
[40] Optimal Time Point for 68Ga-PSMA-11 PET/CT Imaging in the Assessment of Suspected Metastatic Prostate Cancer in the Bladder of Postprostatectomy Patient
Xu, Guofan
Lu, Yang
CLINICAL NUCLEAR MEDICINE, 2021, 46 (08) : 675 - 676

← 1 2 3 4 5 →